HGFR / c-MET Antibody (Antigen Affinity Purified)

HGFR / c-MET Antibody ( Antigen Affinity Purified ) Datasheet

HGFR / c-MET Antibody Product Information

• Immunogen: Recombinant Human HGFR / c-MET protein (Catalog#10692-H08H)
• Antibody Type: Rabbit Polyclonal Antibody ( Antibody Purification Platform )
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: Produced in rabbits immunized with purified, recombinant Human HGFR / c-MET (rh HGFR / c-MET; Catalog#10692-H08H; NP_000236; Met 1-Thr 932). HGFR / c-MET specific IgG was purified by Human HGFR / c-MET affinity chromatography.

HGFR / c-MET Antibody Usage Guide

• Specificity: Human HGFR / c-MET
• Immunochemistry: IHC-P: 0.1-2 μg/mL

  

  Immunochemical staining of human HGFR in human gallbladder with rabbit polyclonal antibody (1 μg/mL, formalin-fixed paraffin embedded sections). Positive staining was localized to epithelium.

• Direct ELISA: This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human C-Met.
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

HGFR / c-MET Antibody Background

The proto-oncogene MET encoded product MET (mesenchymal-epithelial transition factor), also known as c-Met or hepatocyte growth factor receptor (HGFR), is a multifaceted regulator of growth, motility, and invasion, and is normally expressed by cells of epithelial origin. As the prototypic member of a small subfamily of growth factor receptors, c-Met/HGFR is synthesized as a single chain precursor, and is processed into a mature disulfide-linked heterodimer composed of a extracellular α subunit and a transmembrane β subunit via post-translational cleavage. c-Met/HGFR is identified as a glycosylated receptor tyrosine kinase (RTK), and HGF is the only known ligand. Following ligand binding and autophosphorylation, c-Met/HGFR transmits intercellular signals using a unique multisubstrate docking site which mediates the binding of multiple SH2-containing adapter proteins such as Grb2, SHC, Crk/CRKL, as well as Gab1. Normal c-Met/HGFR signaling is essential for embryonic development, tissue repair or wound healing, whereas aberrantly active c-Met/HGFR has been strongly implicated in tumorigenesis, particularly in the development of invasive and metastatic phenotypes. Two transcript variants encoding different isoforms have been identified.

References

1. Bottaro, D.P. et al., 1991, Science. 251: 802-804.
2. Birchmeier, C. et al., 2003, Nat. Rev. Mol. Cell Biol. 4: 915-925.
3. Weidner, K.M. et al., 1996, Nature. 384: 173-176.
4. Pennacchietti, S. et al., 2003, Cancer. Cell. 3: 347-361.
5. Boccaccio, C. et al., 2006, Nat. Rev. Cancer. 6: 637-645.
6. Chmielowiec, J. et al., 2007, J.Cell. Biol. 177: 151-162.
7. Yu, Y.L. et al., 2002, Cancer. Res. 62: 2951-2956.
8. Furge, K.A. et al., 2000, Oncogene. 19: 5582-5589.